Company Overview
LENSAR, Inc. operates as a commercial-stage medical device company dedicated to the design, development, and marketing of laser systems used for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism within the United States. The firm functions within the Healthcare sector, specifically focusing on the Medical Devices industry, an environment where innovation in optical technology and surgical precision defines competitive standing. This organization employs approximately 140 individuals and maintains a market capitalization of $72.50M, reflecting its status as a mid-cap entity in the specialized medical equipment space. The company reported annual revenue of $59.14M over the trailing twelve months, indicating a substantial operational footprint that supports its product-focused strategy in a high-value healthcare market.
Financial Health
The company generated revenue of $59.14M for the trailing twelve months while reporting a net income of $-51,524,000 and an EBITDA of $-4,209,000, highlighting a significant divergence between top-line sales and bottom-line profitability that points to substantial cost structures or one-time expenses impacting the net income figure. Despite the negative net income and negative EBITDA, the firm demonstrated financial flexibility by generating free cash flow of $19.57M, suggesting that operational cash generation remains robust enough to fund capital needs or repay obligations without immediate external financing. Profitability metrics reveal a gross margin of 46.1%, which indicates strong pricing power or high-value manufacturing processes, while the operating margin stands at -16.1% and the profit margin is -87.1%, signaling that significant operating expenses are currently eroding gross profits before reaching the net income level. The balance sheet shows a cash position of $16.87M against total debt of $2.88M, with a debt-to-equity ratio listed as N/A, implying that the company relies primarily on equity or cash reserves rather than leveraged debt financing. Liquidity is maintained with a current ratio of 1.24, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, though the buffer is relatively tight. Return on Equity is recorded at -422.3% and Return on Assets at -8.2%, metrics that reveal that management has not yet achieved positive returns on the capital invested in the business, a common characteristic for commercial-stage medical device firms still scaling their market penetration.
Valuation Assessment
Valuation multiples for the stock include a trailing P/E ratio of N/A and a forward P/E of -24.28, where the negative forward P/E implies that analysts project the company will continue to report losses in the coming period, preventing the calculation of a traditional earnings-based multiple. The price-to-book ratio is reported as -2.80, a negative figure that suggests the market is pricing the company's equity below its book value, often seen in firms with significant intangible assets or those currently unprofitable. Alternative valuation metrics such as a price-to-sales ratio of 1.23 and an EV/EBITDA of -17.18 are utilized instead, indicating that investors are valuing the firm based on its sales volume and enterprise value relative to earnings power rather than current profitability. The stock has traded between a 52-week high of $14.58 and a 52-week low of $5.35, placing the current valuation within a range that reflects market volatility and sentiment regarding the company's path to profitability. The stock exhibits a beta of 0.73, which indicates that the share price is expected to be less volatile than the broader market, moving at approximately 27% less intensity than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth for the year-over-year period is recorded at 5.7%, while earnings growth is listed as N/A due to the company's continued losses, implying that top-line expansion is currently the primary driver of activity rather than bottom-line improvement. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all of its earnings, even the negative ones, to fund research, development, and commercialization efforts. Consequently, the organization reinvests its available cash reserves and operating cash flows back into the business to accelerate the adoption of its laser systems rather than distributing income to shareholders. The overall growth and income profile is characterized by steady top-line expansion and a complete reliance on internal capital generation and cash reserves to fund operations and growth initiatives in the absence of dividend distributions or significant earnings growth.